Aug 2026· Small· pp.
e75388
· 0 citations· 26 references
Medicine
TL;DR
The collaboration of two types of CMNPs using a double-layered spherical scaffold efficiently suppressed the development of multiple colorectal cancer models and provides a new solution for the collaboration of CMNPs in tumor immunogene therapy.
Abstract
Biomimetic technology has high potential for enhancing cancer immunogene therapy. Cell membrane-coated nanoparticles (CMNPs) obtain extra targeting, recognition, and signaling transduction functions. However, a single kind of CMNPs is limited when facing complicated tumor immunogene therapy. Here reported the collaboration of two types of CMNPs using a double-layered spherical scaffold. This scaffold was prepared by stacking photosensitive hydrogels with two concentrations. After implantation, the two layers degraded successively within 5-8 days, enabling sequential and controlled release of payloads. Based on this, a MG-709 double-layered formulation which co-delivered cancer cell membrane-coated nanoparticle/siRNA complex (siStat3@CMP) in the outer layer, and DC membrane-coated nanoparticle/cancer cell lysate complex (DMLD) in the inner layer. The results demonstrated that siStat3@CMP was released first and exerted its apoptosis-inducing effect, resulting in the release of tumor-associated antigens (TAAs). Subsequently, TAAs as well as immune cells migrated into the inner layer, where they worked together with DMLD to ignite immune responses. The activated immune cells were then released to perform immunotherapeutic effects. Facilitated by this mechanism, in situ implantation of the MG-709 scaffold efficiently suppressed the development of multiple colorectal cancer models. The study provides a new solution for the collaboration of CMNPs in tumor immunogene therapy.
Cancer remains a major health concern worldwide, with the need to identify better and more specific treatment measures. The concept of using metallic nanoparticles in drug delivery has attracted significant attention due to their distinct physicochemical characteristics, including surface area, size, and multifunctiona...
Hiti Narula, R. Kamal, Thakur Gurjeet Singh et al.· Nanomedicine: Nanotechnology...· 0 citations
Therapeutic tumor vaccinations are promising for cancer immunotherapy. However, challenges like inadequate antigen encapsulation, weak immune activation, and an immunosuppressive tumor microenvironment limit their efficacy. To overcome these, an injectable Nano-in-Gel vaccine composed of porcine lung-derived extracellu...
Jie Wu, Xin-Xin Bu, Zi Liu et al.· International Journal of Pha...· 0 citations
BACKGROUND
Cancer immunotherapy has shown considerable promise, particularly through dendritic cell (DC)-based vaccines, which are capable of inducing potent, durable, and tumor-specific immune responses. However, their clinical efficacy remains limited by the immature phenotype of DCs, inefficient antigen presentation...
Atefeh Eteghadi, N. Taghipour, S. Hosseinzadeh et al.· Biochemical and Biophysical...· 0 citations
Breast cancer relapse and therapeutic resistance recurrence are mainly due to the presence of breast cancer-associated cancer stem cells (bCSCs), which are inadequately eradicated by conventional chemotherapeutic agents. To mitigate these challenges, we engineered an injectable in situ-forming gelatin hydrogel capable...
Cancer remains a major global health challenge, and nanoparticle-based drug delivery systems have emerged as a promising strategy for targeted cancer therapy. However, clinical translation is still limited by an incomplete understanding of how nanoparticles navigate the tumor microenvironment (TME) throughout the deliv...
Meng-Xin Ban, Si-Fang Zhao, Zi-Yu Liu et al.· Pharmaceutics· 0 citations
Integrating nanoparticles (NPs) with living cells into a unified therapeutic system remains a major methodological challenge. Here, we describe a robust and modular bioorthogonal strategy for constructing cell-nanoparticle hybrids (CNHs) via sequential thiazolidine formation and SpyCatcher/SpyTag ligation. This two-s...